ZUPLENZ for postoperative nausea and vomiting (PONV)


PONV occurs in up to 61% of patients at risk of nausea and vomiting†20



  • Postoperative nausea and vomiting is a common side effect after anesthesia20-22
  • Pain medications given during surgery may cause postoperative nausea and vomiting23

Postsurgery1,9



  • 54% of patients experienced no postoperative emesis1,9
  • 5-HT3 receptor antagonists are recommended by major guidelines for management of PONV13,24

ASA | ASHP

Important Safety information

  • In clinical studies of postsurgical use, the most common adverse event occurring at a rate significantly different from placebo was headache (9% vs 5%)

ZUPLENZ delivers the trusted efficacy of ondansetron in a quick-dissolving film

  • Can be dosed prior to surgery1
  • Easy to take for patients who have trouble swallowing tablets or who refuse suppositories
  • Dissolves rapidly in the mouth in about 10 seconds14-16
  • Safe and well tolerated
  • Nonsedating1

ASA=American Society of Anesthesiologists.
ASHP=American Society of Health-System Pharmacists.


*Not an actual patient.


For the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

The concomitant use of apomorphine with ondansetron is contraindicated based upon reports of profound hypotension and loss of consciousness.

Patients known to have hypersensitivity to ondansetron and to other selective 5-HT3 receptor antagonists should not take ZUPLENZ. Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported. Rarely and predominantly with intravenous ondansetron, transient electrocardiographic changes, including QT interval prolongation, have occurred.

The use of ZUPLENZ in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension. ZUPLENZ does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction.

The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron for prevention of nausea and vomiting associated with cancer chemotherapy or radiotherapy were headache, malaise/fatigue, constipation, and diarrhea. For postoperative nausea and vomiting, headache occurred at a rate significantly different from placebo.

ZUPLENZ is available by prescription only. Please click here for complete Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

For more information about ZUPLENZ, call 1-866-662-7199